ai-models is the sole category represented across all 1 tracked stories. Bayer Aktiengesellschaft is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 45 original sources per story, versus 2.6 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Ocular Therapeutix, Inc.
ai-models is the sole category represented across all 1 tracked stories. Bayer Aktiengesellschaft is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 45 original sources per story, versus 2.6 across the same-window beat baseline. The 7 average consequence score is above the beat benchmark of 6.3 in the same window. We currently track 1 AI story that mention Ocular Therapeutix, Inc., all published on February 19, 2026.
Stories tracked
1
Sources per story
45
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 140 AI stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Ocular Therapeutix, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Indian IT giants faced a significant sell-off as investors weighed the disruptive potential of generative AI on traditional outsourcing models. Meanwhile, the biotech sector experienced extreme volatility following high-stakes Phase 3 trial results from Compass Pathways and Ocular Therapeutix.